Definitive Healthcare Corp DH.OQ DH.O is expected to show a fall in quarterly revenue when it reports results on November 6 for the period ending September 30 2025
The Framingham Massachusetts-based company is expected to report a 5.1% decrease in revenue to $59.488 million from $62.7 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.
LSEG's mean analyst estimate for Definitive Healthcare Corp is for earnings of 6 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 9 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Definitive Healthcare Corp is $4.50, about 36.4% above its last closing price of $2.86
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | 0.05 | 0.05 | 0.07 | Beat | 40.5 |
Mar. 31 2025 | 0.02 | 0.02 | 0.05 | Beat | 107.6 |
Dec. 31 2024 | 0.07 | 0.07 | 0.08 | Beat | 12.9 |
Sep. 30 2024 | 0.08 | 0.08 | 0.10 | Beat | 25.5 |
Jun. 30 2024 | 0.09 | 0.09 | 0.09 | Met | 3.7 |
Mar. 31 2024 | 0.08 | 0.08 | 0.08 | Met | -1.9 |
Dec. 31 2023 | 0.08 | 0.08 | 0.07 | Missed | -8.4 |
Sep. 30 2023 | 0.07 | 0.06 | 0.09 | Beat | 49.1 |
This summary was machine generated November 4 at 21:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments